Eckert & Ziegler Expands Ga-68 Activities in Japan in Collaboration with Novartis

Eckert & Ziegler, a medical and radiation technology company, announced on February 28, 2024 the expansion of its Gallium-68 (Ga-68)-labeled diagnostics business in Japan, in collaboration with Novartis Pharma KK. is accompanied by a clinical study, notified to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), using exclusively the Ge-68/Ga-68 GalliaPharm® generator from Eckert & Ziegler as a source of Ga- 68.

The clinical study (NCT06240741) aims to evaluate the diagnostic performance of Positron Emission Tomography (PET)/Computed Tomography (CT) imaging with [68Ga]Ga-DOTA-TATE in patients with neuroendocrine neoplasms (NEN) , tumors considered rare but the number of diagnoses of which is increasing worldwide. The first GalliaPharm® generator was delivered in January 2024, and others will follow until mid-2025. Successful market approval could result in significant sales potential for Eckert & Ziegler.

Dr. Harald Hasselmann, CEO of the German firm, highlights the importance of this collaboration not only for the expansion of their radioisotope supply business in Japan, but also for improving access to cancer therapies and diagnostics. for Japanese patients.